
Partner-funded development marks an important milestone for VELDONA, with BioPhoenix funding and advancing clinical and regulatory development for two initial indications Development funding is additional to the framework; Ainos retains core platform ownership, product supply opportunities and contractual participation in downstream commercial revenue HOUSTON, TX / ACCESS Newswire / September 24, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has entered into a VELDONA® License Agreement with BioPhoenix Co., Ltd. ("BioPhoenix"), establishing a collaboration framework with a potential aggregate value of $10 million.










